Department of Surgical Sciences, Haukeland University Hospital, Bergen, Norway.
World Neurosurg. 2012 Dec;78(6):658-69. doi: 10.1016/j.wneu.2012.03.024. Epub 2012 Apr 4.
The optimal management of patients with recurrent glioblastoma multiforme (GBM) is a subject of controversy. These patients may be candidates for both reoperation and/or gamma knife surgery (GKS). Few studies have addressed the role of GKS for relapsing gliomas, and the results have not been compared with reoperation. To validate the efficacy and safety of GKS, we compared the survival and complication rates of GKS and reoperation for recurrent GBMs.
This study retrospectively reviewed 77 consecutive patients with histopathologically confirmed GBMs retreated for recurrent GBM between 1996 and 2007. Thirty-two patients underwent GKS, 26 reoperation and 19 both procedures.
The median time from the second intervention to tumor progression was longer after GKS than after resection, P = 0.009. Median survival after retreatment was 12 months for the 51 patients receiving GKS compared with 6 months for reoperation only (P = 0.001, hazard ratio [HR] 2.4), and 19 months versus 16 months from the time of primary diagnosis (P = 0.021, HR 1.8). A multivariate analysis adjusted for possible confounding factors (tumor volume, recursive partitioning analysis class, neurological deficits, time to recurrence, adjuvant therapy, and tumor location) showed significantly longer survival for patients treated with GKS, both from retreatment (P = 0.013, HR 4.1) and from primary diagnosis (P = 0.002, HR 5.8). The adjusted results were still significant after separate analysis according to tumor volume <5 mL, 5 to 20 mL, and >20 mL. The complications rate was 9.8% after GKS and 25.2% after reoperation.
GKS may be an alternative to open surgery for small GBMs at the time of recurrences, with a significantly lower complication rate and a possible survival benefit compared with reoperation.
复发性多形性胶质母细胞瘤(GBM)的最佳治疗方法存在争议。这些患者可能是再次手术和/或伽玛刀手术(GKS)的候选者。很少有研究探讨 GKS 治疗复发性胶质瘤的作用,而且结果也没有与再次手术进行比较。为了验证 GKS 的疗效和安全性,我们比较了 GKS 和再次手术治疗复发性 GBM 的生存率和并发症发生率。
本研究回顾性分析了 1996 年至 2007 年间因复发性 GBM 接受治疗的 77 例连续患者的临床病理资料。32 例患者接受 GKS 治疗,26 例患者接受再次手术治疗,19 例患者同时接受两种治疗。
GKS 后肿瘤进展的中位时间长于再次手术切除后的时间,P = 0.009。51 例接受 GKS 治疗的患者的中位无进展生存期为 12 个月,而仅接受再次手术治疗的患者为 6 个月(P = 0.001,风险比[HR]2.4),从首次诊断时间开始为 19 个月和 16 个月(P = 0.021,HR 1.8)。对可能的混杂因素(肿瘤体积、递归分区分析分级、神经功能缺损、复发时间、辅助治疗和肿瘤位置)进行多变量分析后显示,接受 GKS 治疗的患者从再次治疗(P = 0.013,HR 4.1)和从首次诊断(P = 0.002,HR 5.8)的时间来看,生存率显著延长。根据肿瘤体积<5 mL、5-20 mL 和>20 mL 进行单独分析后,调整结果仍然显著。GKS 的并发症发生率为 9.8%,再次手术的并发症发生率为 25.2%。
对于复发时的小 GBM,GKS 可能是开放性手术的替代方法,其并发症发生率较低,与再次手术相比可能具有生存优势。